Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: 4 | Rare Historical Photos

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

MarketBeat

Immunovant Q4 Earnings Call Highlights

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna. Matthew Klein, CEO of Roivant, said the company has had “a pret

MarketBeat

Staged claims and Israeli hoaxes: Debunking viral conspiracy theories about hantavirus

Misinformation about hantavirus has run rampant on social media, with online users reviving viral COVID-19 theories to spread fake news about the outbreak.

Euronews

From analysis to the latest developments in health,
read the most diverse news in one place.

Is There A Cure For Hantavirus Infection? 'Breathed In' Virus Kills 38% Of Patients, Scientists Race For Vaccine

A deadly cruise ship outbreak of the Andes strain has revived global interest in a long‑delayed hantavirus cure, as scientists warn that early hospital care can make the difference between survival and a 38% fatality risk.

International Business Times UK

Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality.

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

Barchart

Is Wall Street Bullish or Bearish on Moderna Stock?

Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Barchart

Major trial for human bird flu vaccine launches

Around 4,000 people will be recruited for the study, the majority of which will be in the UK.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Bird flu vaccine trial begins to fight ‘real possibility’ of virus threat for humans

The vaccine will utilise mRNA technology similar to that employed in Covid-19 jabs

The Independent UK

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to announce its fiscal first-quarter earnings next month, and analysts project a high single-digit decline in losses.

Barchart

What to know about OpenAI's new model for life sciences research GPT-Rosalind

The GPT-Rosalind model is designed to accelerate biological research and drug discovery.

Euronews

Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international contracts may surprise bears in 2026.

Barchart

America is handing its mRNA lead to China—and RFK Jr. is to blame

Political interference is driving biotech investment overseas, and U.S. patients and workers will pay the price.

Fortune

The S&P 500's 3 Best-Performing Stocks So Far in 2026

Despite a broad market selloff, SNDK, TPL, and MRNA stand out as the S&P 500's 3 best-performing stocks in 2026, each operating in a different sector.

MarketBeat

US vaccine panel retreats from mRNA Covid review ahead of midterms

Advisers to RFK Jr drop the plan to end federal guidance amid Republican worries about the political impact

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Moderna Stock Outperforming the Dow?

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

The Independent UK

FDA to offer bonus payments to staffers who complete speedy drug reviews

The head of the Food and Drug Administration plans to start offering bonus payments to agency drug reviewers who complete their work ahead of the schedule

The Conversation

FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from public health experts.

The Independent UK

FDA will drop two-study requirement for new drug approvals, aiming to speed access

The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

Moderna shares extend gains as FDA reverses its refusal-to-file decision on the firm’s influenza vaccine. Here’s why MRNA shares still aren’t attractive to own in 2026.

The Guardian - US

FDA reverses course and will review Moderna’s mRNA-based flu vaccine

US drug regulator originally refused to consider application, fueling critics’ concern about alleged ‘anti-vaccine agenda’

The Independent UK

Moderna says the FDA will consider its new flu shot after resolving a public dispute

Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults after all

The Guardian - US

FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’

Experts say ‘they’re just coming up with reasons’ as agency says application lacked ‘adequate and well controlled’ trial

Reason

Clinical Trials Show Moderna's New mRNA Flu Vaccine Is Safe and Effective. FDA Won't Even Consider It.

An overzealous government agency suppresses medical innovation yet again.

The Conversation

FDA rejects Moderna’s mRNA flu vaccine application - for reasons with no basis in the law

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine.

The Independent UK

First mRNA vaccine to be produced in UK approved by regulators

The Moderna Innovation and Technology Centre will make millions of cutting-edge mRNA vaccines

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

the Food and Drug Administration

232 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.